{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:41:09Z","timestamp":1786236069617,"version":"build-2736575974"},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1053\/j.seminoncol.2015.09.003","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T13:27:36Z","timestamp":1444829256000},"page":"107-115","source":"Crossref","is-referenced-by-count":31,"title":["Novel routes for administering chemoprevention: local transdermal therapy to the breasts"],"prefix":"10.1053","volume":"43","author":[{"given":"Oukseub","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9880","key":"10.1053\/j.seminoncol.2015.09.003_bib1","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","article-title":"Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data","volume":"381","author":"Cuzick","year":"2013","journal-title":"Lancet"},{"issue":"25","key":"10.1053\/j.seminoncol.2015.09.003_bib2","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"},{"issue":"9922","key":"10.1053\/j.seminoncol.2015.09.003_bib3","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2013","journal-title":"Lancet"},{"issue":"18","key":"10.1053\/j.seminoncol.2015.09.003_bib4","first-page":"1371","article-title":"Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J NatlCancer Inst"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.003_bib5","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s10434-001-0580-9","article-title":"Patient reluctance toward tamoxifen use for breast cancer primary prevention","volume":"8","author":"Port","year":"2001","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.003_bib6","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1999.17.9.2659","article-title":"Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"17","author":"Day","year":"1999","journal-title":"J Clin Oncol"},{"issue":"106","key":"10.1053\/j.seminoncol.2015.09.003_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002368","article-title":"Preclinical and clinical evaluation of intraductally administered agents in early breast cancer","volume":"3","author":"Stearns","year":"2011","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.003_bib8","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1093\/carcin\/bgs248","article-title":"Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: implications for breast cancer chemoprevention in at-risk populations","volume":"33","author":"Chun","year":"2012","journal-title":"Carcinogenesis"},{"issue":"9354","key":"10.1053\/j.seminoncol.2015.09.003_bib9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","article-title":"Overview of the main outcomes in breast-cancer prevention trials","volume":"361","author":"Cuzick","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.003_bib10","first-page":"332","article-title":"Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial","volume":"1","author":"Dunn","year":"2010","journal-title":"Int J Mol Epidemiol Genet"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.003_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-2964(80)90156-5","article-title":"Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model","volume":"16","author":"Jordan","year":"1980","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.003_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1476-5381.1980.tb10912.x","article-title":"Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships","volume":"71","author":"Allen","year":"1980","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.003_bib13","first-page":"112","article-title":"Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells","volume":"44","author":"Katzenellenbogen","year":"1984","journal-title":"Cancer Res"},{"issue":"36","key":"10.1053\/j.seminoncol.2015.09.003_bib14","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1200\/JCO.2005.03.3266","article-title":"Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes","volume":"23","author":"Goetz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.003_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-006-9428-0","article-title":"The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen","volume":"101","author":"Goetz","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.003_bib16","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1158\/0008-5472.CAN-08-3933","article-title":"The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells","volume":"69","author":"Wu","year":"2009","journal-title":"Cancer Res"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.003_bib17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/DAD.0b013e3180325d6b","article-title":"Contrary view: the breast is not an organ per se, but a distinctive region of skin and subcutaneous tissue","volume":"29","author":"Ackerman","year":"2007","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.003_bib18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1245\/s10434-007-9709-9","article-title":"The lymphatic anatomy of the breast and its implications for sentinel lymph node biopsy: a human cadaver study","volume":"15","author":"Suami","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.003_bib19","series-title":"Percutaneous absorption of steroids","first-page":"219","article-title":"treatment of benign breast disease by progesterone applied topically","author":"Sitruk-Ware","year":"1980"},{"key":"10.1053\/j.seminoncol.2015.09.003_bib20","series-title":"Endocrinology of cystic breast disease","first-page":"93","article-title":"Steroid concentrations in serum, glandular breast tissue, and breast cyst fluid of control and P-treated patients","author":"De Boever","year":"1983"},{"key":"10.1053\/j.seminoncol.2015.09.003_bib21","series-title":"Current therapy in endocrinology","first-page":"428","article-title":"Hormonal therapy of benign breast disease","author":"Mauvais-Jarvis","year":"1983"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.003_bib22","first-page":"477","article-title":"[The treatment of benign pathological conditions of the breasts with progesterone and progestogens. The results according to the type of breast condition (260 case records) (author\u2019s transl)]","volume":"7","author":"Mauvais-Jarvis","year":"1978","journal-title":"J Gynecol Obstet Biol Reprod (Paris)"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.003_bib23","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1210\/jcem-55-3-428","article-title":"Estradiol 17 beta-hydroxysteroid dehydrogenase activity in human breast fibroadenomas","volume":"55","author":"Fournier","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.003_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF01807330","article-title":"Antiestrogen action of progesterone in breast tissue","volume":"8","author":"Mauvais-Jarvis","year":"1986","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.003_bib25","first-page":"1521","article-title":"trans-4-Hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast","volume":"46","author":"Mauvais-Javis","year":"1986","journal-title":"Cancer Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.003_bib26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/BF00685799","article-title":"Phase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue","volume":"36","author":"Pujol","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.003_bib27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-007-9507-x","article-title":"A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women","volume":"106","author":"Mansel","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"14","key":"10.1053\/j.seminoncol.2015.09.003_bib28","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1158\/1078-0432.CCR-13-3045","article-title":"A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast","volume":"20","author":"Lee","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.003_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jnci\/90.1.37","article-title":"Estrogen receptor expression in benign breast epithelium and breast cancer risk","volume":"90","author":"Khan","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2015.09.003_bib30","first-page":"1817","article-title":"Estrogen and progesterone receptors in the normal female breast","volume":"51","author":"Ricketts","year":"1991","journal-title":"Cancer Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.003_bib31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/00000658-199906000-00013","article-title":"Subareolar versus peritumoral injection for location of the sentinel lymph node","volume":"229","author":"Klimberg","year":"1999","journal-title":"Ann Surg"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.003_bib32","first-page":"10","article-title":"Prospective randomized trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer","volume":"13","author":"Povoski","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"9336","key":"10.1053\/j.seminoncol.2015.09.003_bib33","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.003_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2004.09.014","article-title":"Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature","volume":"116","author":"Cosman","year":"2005","journal-title":"Thromb Res"},{"issue":"13","key":"10.1053\/j.seminoncol.2015.09.003_bib35","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1200\/JCO.2005.06.064","article-title":"Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen","volume":"23","author":"Rouanet","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.003_bib36","series-title":"Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen","author":"Le Nestour","year":"2009"},{"key":"10.1053\/j.seminoncol.2015.09.003_bib37","series-title":"Reduction of breast density with 4-hydroxy tamoxifen. US 2004\/0138314 A12004","author":"Bua","year":"2004"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.003_bib38","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1177\/0192623314525688","article-title":"Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats","volume":"42","author":"Schweikart","year":"2014","journal-title":"Toxicol Pathol"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.003_bib39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1124\/jpet.105.100511","article-title":"Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells","volume":"318","author":"Lim","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.003_bib40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00280-004-0926-7","article-title":"Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen","volume":"55","author":"Lim","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.003_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/BCTT.S20821","article-title":"In vitro human skin permeation of endoxifen: potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast","volume":"3","author":"Lee","year":"2011","journal-title":"Breast Cancer Targets Ther"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.003_bib42","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.addr.2003.10.025","article-title":"Penetration enhancers","volume":"56","author":"Williams","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.003_bib43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/1523-1747.ep12475655","article-title":"Action of penetration enhancers on human skin as assessed by the permeation of model drugs 5-fluorouracil and estradiol. I. Infinite dose technique","volume":"91","author":"Goodman","year":"1988","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.003_bib44","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1021\/js9601041","article-title":"Mutual hairless rat skin permeation-enhancing effect of ethanol\/water system and oleic acid","volume":"85","author":"Kim","year":"1996","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.003_bib45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/10717540802006898","article-title":"Skin permeation enhancement of diclofenac by fatty acids","volume":"15","author":"Kim","year":"2008","journal-title":"Drug Deliv"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.003_bib46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0378-5173(02)00540-9","article-title":"Effect of enhancers and retarders on percutaneous absorption of flurbiprofen from hydrogels","volume":"250","author":"Fang","year":"2003","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.003_bib47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.0022-202x.2001.01353.x","article-title":"In vitro visualization and quantification of oleic acid induced changes in transdermal transport using two-photon fluorescence microscopy","volume":"117","author":"Yu","year":"2001","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.003_bib48","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1248\/bpb.18.1566","article-title":"Percutaneous penetration of fluorescein isothiocyanate-dextrans and the mechanism for enhancement effect of enhancers on the intercellular penetration","volume":"18","author":"Ogiso","year":"1995","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.003_bib49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10787-009-8049-8","article-title":"Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung","volume":"17","author":"Harris","year":"2009","journal-title":"Inflammopharmacology"},{"issue":"13","key":"10.1053\/j.seminoncol.2015.09.003_bib50","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/cncr.26643","article-title":"Pregnancy-associated breast cancer: an entity needing refinement of the definition","volume":"118","author":"Borges","year":"2012","journal-title":"Cancer"},{"issue":"22","key":"10.1053\/j.seminoncol.2015.09.003_bib51","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1158\/1078-0432.CCR-12-2603","article-title":"Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer","volume":"19","author":"Howe","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.003_bib52","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/jnci\/djn036","article-title":"Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer","volume":"100","author":"Visscher","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.003_bib53","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/jnci\/djq101","article-title":"Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis","volume":"102","author":"Kerlikowske","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2015.09.003_bib54","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12609-014-0144-1","article-title":"Advances in preventive therapy for estrogen-receptor-negative breast cancer","volume":"6","author":"Litzenburger","year":"2014","journal-title":"Curr Breast Cancer Rep"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.003_bib55","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/0008-5472.CAN-03-2912","article-title":"The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention","volume":"65","author":"Kong","year":"2005","journal-title":"Cancer Res"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.003_bib56","first-page":"997","article-title":"Retinoic acid receptor- and retinoid X receptor-selective retinoids activate signaling pathways that converge on AP-1 and inhibit squamous differentiation in human bronchial epithelial cells","volume":"7","author":"Lee","year":"1996","journal-title":"Cell Growth Differ"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.003_bib57","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1074\/jbc.M804721200","article-title":"Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1","volume":"284","author":"Uray","year":"2009","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.003_bib58","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/annonc\/mdl047","article-title":"Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer","volume":"17","author":"Veronesi","year":"2006","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.003_bib59","first-page":"467","article-title":"Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069","volume":"11","author":"Wu","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"14","key":"10.1053\/j.seminoncol.2015.09.003_bib60","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-08-0040","article-title":"Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268","volume":"14","author":"Liby","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.003_bib61","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1158\/1940-6207.CAPR-08-0107","article-title":"Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib","volume":"2","author":"Medina","year":"2009","journal-title":"Cancer Prev Res"},{"issue":"13","key":"10.1053\/j.seminoncol.2015.09.003_bib62","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1158\/0008-5472.CAN-05-1823","article-title":"Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas","volume":"66","author":"Woditschka","year":"2006","journal-title":"Cancer Res"},{"issue":"20","key":"10.1053\/j.seminoncol.2015.09.003_bib63","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1158\/1078-0432.CCR-06-2681","article-title":"The rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice","volume":"13","author":"Li","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2015.09.003_bib64","doi-asserted-by":"crossref","unstructured":"Brown PHAB, Miller A, Isaacs C, et al. Phase II trial of bexarotene in women at high risk of breast cancer: comparison of protein and RNA biomarkers. In: 7th Annual AACR International Frontiers in Cancer Prevention Research Meeting. Chicago; 2008:178-179.","DOI":"10.1158\/1940-6207.PREV-08-CN04-04"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.003_bib65","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.003_bib66","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.003_bib67","first-page":"502","article-title":"Physiological action of progesterone in target tissues","volume":"18","author":"Graham","year":"1997","journal-title":"Endocrine Rev"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.003_bib68","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1517\/17425255.2012.695775","article-title":"Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment","volume":"8","author":"Melis","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.003_bib69","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/AOG.0b013e3181705d0e","article-title":"CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial","volume":"111","author":"Levens","year":"2008","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.003_bib70","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1210\/endo.140.3.6581","article-title":"The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins","volume":"140","author":"Wagner","year":"1999","journal-title":"Endocrinology"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.003_bib71","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jsbmb.2003.12.004","article-title":"In vitro antiprogestational\/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone","volume":"88","author":"Attardi","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.003_bib72","first-page":"167","article-title":"Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestin","volume":"18","author":"Wiehle","year":"2007","journal-title":"Oncol Rep"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.003_bib73","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1158\/1940-6207.CAPR-10-0244","article-title":"CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis","volume":"4","author":"Wiehle","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"8, Suppl 1","key":"10.1053\/j.seminoncol.2015.09.003_bib74","article-title":"In vitro and in vivo transdermal delivery of CDB4124, a progesterone receptor modulator: a potential method for breast cancer prevention","volume":"73","author":"Lee","year":"2013","journal-title":"Cancer Res"},{"issue":"49","key":"10.1053\/j.seminoncol.2015.09.003_bib75","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1002\/anie.201105508","article-title":"Dendrimer-mediated multivalent binding for the enhanced capture of tumor cells","volume":"50","author":"Myung","year":"2011","journal-title":"Angewandte Chem"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.003_bib76","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1021\/ar600012y","article-title":"Nanoparticle interaction with biological membranes: does nanotechnology present a Janus face?","volume":"40","author":"Leroueil","year":"2007","journal-title":"Accounts Cehm Res"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.003_bib77","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrc1958","article-title":"Polymer conjugates as anticancer nanomedicines","volume":"6","author":"Duncan","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.003_bib78","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.chembiol.2006.11.015","article-title":"The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform","volume":"14","author":"Hong","year":"2007","journal-title":"Chem Biol"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.003_bib79","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1021\/bc900029k","article-title":"The role of ganglioside GM1 in cellular internalization mechanisms of poly(amidoamine) dendrimers","volume":"20","author":"Hong","year":"2009","journal-title":"Bioconjugate Chem"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.003_bib80","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1021\/bc060077y","article-title":"Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability","volume":"17","author":"Hong","year":"2006","journal-title":"Bioconjugate Chem"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.003_bib81","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1021\/bc049962b","article-title":"Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport","volume":"15","author":"Hong","year":"2004","journal-title":"Bioconjugate Chem"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.003_bib82","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1021\/bm300545b","article-title":"Effect of size, surface charge, and hydrophobicity of poly(amidoamine) dendrimers on their skin penetration","volume":"13","author":"Yang","year":"2012","journal-title":"Biomacromolecules"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.003_bib83","doi-asserted-by":"crossref","first-page":"941","DOI":"10.4155\/tde.12.76","article-title":"Dendritic nanoparticles: the next generation of nanocarriers?","volume":"3","author":"Pearson","year":"2012","journal-title":"Therapeut Deliv"},{"issue":"37","key":"10.1053\/j.seminoncol.2015.09.003_bib84","doi-asserted-by":"crossref","first-page":"10302","DOI":"10.1039\/c1cc14331j","article-title":"Dendron-mediated self-assembly of highly PEGylated block copolymers: a modular nanocarrier platform","volume":"47","author":"Bae","year":"2011","journal-title":"Chem Commun"},{"issue":"17","key":"10.1053\/j.seminoncol.2015.09.003_bib85","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/adfm.201303253","article-title":"Dendron-based micelles for topical delivery of endoxifen: a potential chemo- preventive medicine for breast cancer","volume":"24","author":"Yang","year":"2014","journal-title":"Adv Functional Materials"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.003_bib86","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jps.20745","article-title":"Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers","volume":"96","author":"Cheng","year":"2007","journal-title":"J Pharmaceut Sci"},{"key":"10.1053\/j.seminoncol.2015.09.003_bib87","doi-asserted-by":"crossref","unstructured":"Goetz MP, Suman VA, Reid JR, et al. A first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781). San Antonio, TX: 2013 San Antonio Breast Cancer Symposium.","DOI":"10.1158\/0008-5472.SABCS13-PD3-4"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.003_bib88","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jnci\/95.11.779","article-title":"A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers","volume":"95","author":"Decensi","year":"2003","journal-title":"J Natl Cancer Inst"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775415001682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775415001682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T11:11:20Z","timestamp":1567249880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775415001682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0093775415001682"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2015.09.003","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}